The Effectiveness of Therapeutic Vaccines for the Treatment of Cervical Intraepithelial Neoplasia 3: A Systematic Review and Meta-Analysis

Cervical cancer (CC) is a disease that affects many women worldwide, especially in low-income countries. The human papilloma virus (HPV) is the main causative agent of this disease, with the E6 and E7 oncoproteins being responsible for the development and maintenance of transformed status. In addition, HPV is also responsible for the appearance of cervical intraepithelial neoplasia (CIN), a pre-neoplastic condition burdened by very high costs for its screening and therapy. So far, only prophylactic vaccines have been approved by regulatory agencies as a means of CC prevention. However, these vaccines cannot treat HPV-positive women. A search was conducted in several databases (PubMed, Scopus, Web of Science, and ClinicalTrials.gov) to systematically identify clinical trials involving therapeutic vaccines against CIN 3. Histopathological regression data, immunological parameters, safety, DNA clearance, and vaccine efficacy were considered from each selected study, and from the 102 articles found, 8 were selected based on the defined inclusion criteria. Histopathological regression from CIN 3 to CIN < 1 was 22.1% (95% CI: 0.627–0.967; p-value = 0.024), showing a vaccine efficacy of 23.6% (95% CI; 0.666–0.876; p-value < 0.001). DNA clearance was assessed, and the risk of persistent HPV DNA was 23.2% (95% CI: 0.667–0.885; p-value < 0.001). Regarding immunological parameters, immune responses by specific T-HPV cells were more likely in vaccinated women (95% CI: 1.245–9.162; p-value = 0.017). In short, these studies favored the vaccine group over the placebo group. This work indicated that therapeutic vaccines are efficient in the treatment of CIN 3, even after accounting for publication bias.info:eu-repo/semantics/publishedVersio

p53 Function Re-Establishment and Apoptosis Induction in Cervical Cancer Cells

Funding Information: Funding: This work was supported by the Foundation for Science and Technology (FCT), through funds from the State Budget, and by the European Regional Development Fund through the “Pro-grama Operacional Regional do Centro (Centro 2020)—Sistema de Apoio à Investigação Científica e Tecnológica—Programas Integrados de IC&DT” (Project Centro-01-0145-FEDER-000019—C4—Centro de Competências em Cloud Computing) and the project ref: UIDB/00709/2020. This work was also supported by national funds from FCT—Fundação para a Ciência e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences—UCIBIO and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy—i4HB. D. Gomes also acknowledges the doctoral fellowship from FCT (ref: 2020.06792.BD). This work was also supported by the Ramalingaswami Fellowship (BT/RLF/Re-entry/64/2017), Department of Biotechnology, Govt. of India (V.K.). Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.Cervical cancer is the fourth leading cause of death in women worldwide, with 99% of cases associated with a human papillomavirus (HPV) infection. Given that HPV prophylactic vaccines do not exert a therapeutic effect in individuals previously infected, have low coverage of all HPV types, and have poor accessibility in developing countries, it is unlikely that HPV-associated cancers will be eradicated in the coming years. Therefore, there is an emerging need for the development of anti-HPV drugs. Considering HPV E6’s oncogenic role, this protein has been proposed as a relevant target for cancer treatment. In the present work, we employed in silico tools to discover potential E6 inhibitors, as well as biochemical and cellular assays to understand the action of selected compounds in HPV-positive cells (Caski and HeLa) vs. HPV-negative (C33A) and non-carcinogenic (NHEK) cell lines. In fact, by molecular docking and molecular dynamics simulations, we found three phenolic compounds able to dock in the E6AP binding pocket of the E6 protein. In particular, lucidin and taxifolin were able to inhibit E6-mediated p53 degradation, selectively reduce the viability, and induce apoptosis in HPV-positive cells. Altogether, our data can be relevant for discovering promising leads for the development of specific anti-HPV drugs.publishersversionpublishe

One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis

BACKGROUND: The main control strategy for visceral leishmaniasis in Brazil has been based on the elimination of seropositive dogs, although this is not widely accepted. In this context, the use of a long-lasting protective vaccine against canine visceral leishmaniasis (CVL) has been highly expected. The aim of this work was to determine the timeline kinetics of the cytokine microenvironment derived from circulating leukocytes as supportive immunological biomarkers triggered by Leishmune® vaccine. Cross-sectional kinetic analysis of cellular immunity cytokines was carried out at three times (1, 6 and 12 months) after primovaccination with Leishmune®. In vitro short-term whole blood cultures were stimulated with Leishmania infantum soluble antigen (SLAg). The secreted cytokine signatures and their major sources were determined. RESULTS: At six months after vaccination, Leishmune® induced an increase in IL-8, IFN-γ, IL-17a and TNF-α levels and a decrease in IL-10. Cytokine signature analysis revealed a shift in the microenvironment towards a pro-inflammatory profile mediated by IL-8 and IFN-γ. Both, CD4(+) (↑TNF-α(+) and ↑IFN-γ (+)) and CD8(+) (↑IL-17a and ↓IL-4) T-cells contributed to the acquired immune responses observed after stimulation with SLAg. CONCLUSIONS: The changes observed in the cytokine profile suggested that Leishmune® was able to induce an effective response at six months after primovaccination. After one year, it returned to baseline suggesting the need of additional boosting

Metabolic Profiling of Inga Species with Antitumor Activity.

Funding: This research received no external funding. Acknowledgments: The authors thank Brazilian Research Agencies CNPq, CAPES, and FAPESP, as well as Albrn Care, India.Peer reviewedPublisher PD

Evaluation of mutagenicity and antimutagenicity of different fractions of Pterogyne nitens (Leguminosae), using Tradescantia pallida micronuclei assay

Pterogyne nitens (Fabaceae-Caesalpinioideae) é uma árvore nativa da América do Sul, onde é empregada na medicina popular para o tratamento da ascaridíase. Recentemente, descrevemos o efeito mutagênico do extrato etanólico das folhas de P. nitens. Dessa forma, o presente estudo teve por objetivo aprofundar a avaliação do potencial mutagênico das frações isoladas das folhas de Pterogyne nitens, acetato de etila (AcOEt), n-butanólica (BuOH) e hidroalcóolica (HA). Quando o efeito mutagênico foi observado somente nas maiores concentrações testadas, o potencial antimutagênico também foi avaliado. Os ensaios mutagênicos e antimutagênicos foram realizados utilizando ensaio de micronúcleo em Trandescantia pallida. Na avaliação de mutagenicidade, observou-se o efeito nas frações AcOEt (0,460 mg/mL), BuOH (0,142, 0,285, 0,570 e 1,14 mg/mL) e HA (0,050, 0,100, 0,200 e 0,400 mg/mL). Considerando que o efeito mutagênico da fração AcOEt foi observado somente na concentração mais elevada (0,460 mg/mL), o potencial antimutagênico da mesma foi avaliado. As concentrações de 0,115 e 0,230 mg/mL da fração AcOEt demonstraram atividade antimutagênica. A partir dos resultados do presente estudo, conclui-se que determinadas frações de P. nitens apresentam mutagenicidade (BuOH e HA), enquanto a fração AcOEt apresentou efeito antimutagênico nas maiores concentrações. Esses resultados tornam o estudo da P. nitens bastante promissor, considerando que esta planta possui distribuição geográfica ampla e tem sido pouco estudada.Pterogyne nitens (Fabaceae-Caesalpinioideae) is a tree native to South American, where it is used in folk treatment of ascaridiasis. Recently, we have been describing the mutagenic effect of the ethanol extract of leaves of P. nitens. Thus, the present study aimed at evaluating the mutagenic potential of the ethyl acetate (EtOAc), n- butanol (BuOH) and hydroalcoholic (HA) fractions. When the mutagenic effect was observed only in the highest tested concentrations, the antimutagenic activity was also evaluated. Both mutagenic and antimutagenic assays were performed using T. pallida micronuclei assay. Mutagenicity was observed between different concentrations of the P nitens fractions, EtOAc (0.460 mg/mL), BuOH (0.142, 0.285, 0.570 and 1.14 mg/mL) and HA (0.050, 0.100, 0.200 and 0.400 mg/mL). Whereas the mutagenic effect of the EtOAc fraction was observed in the highest concentration (0.460 mg/mL), its antimutagenic potential was evaluated. The 0.115 and 0.230 mg/mL concentrations of the EtOAc fraction demonstrated antimutagenic activity. Based on the results of the present study we can conclude that some P. nitens fractions (BuOH and HA) demonstrated mutagenic effects whereas the EtOAc fraction shown low mutagenicity and amtimutagenicity in the two higher concentrations. Those results stimulate the studies with P. nitens, which possess spread geographic distribution and it is still low studied

An Intracellular Arrangement of Histoplasma capsulatum Yeast-Aggregates Generates Nuclear Damage to the Cultured Murine Alveolar Macrophages

Histoplasma capsulatum is responsible for a human systemic mycosis that primarily affects lung tissue. Macrophages are the major effector cells in humans that respond to the fungus, and the development of respiratory disease depends on the ability of Histoplasma yeast cells to survive and replicate within alveolar macrophages. Therefore, the interaction between macrophages and H. capsulatum is a decisive step in the yeast dissemination into host tissues. Although the role played by components of cell-mediated immunity in the host's defense system and the mechanisms used by the pathogen to evade the host immune response are well understood, knowledge regarding the effects induced by H. capsulatum in host cells at the nuclear level is limited. According to the present findings, H. capsulatum yeast cells display a unique architectural arrangement during the intracellular infection of cultured murine alveolar macrophages, characterized as a formation of aggregates that seem to surround the host cell nucleus, resembling a crown. This extranuclear organization of yeast-aggregates generates damage on the nucleus of the host cell, producing DNA fragmentation and inducing apoptosis, even though the yeast cells are not located inside the nucleus and do not trigger changes in nuclear proteins. The current study highlights a singular intracellular arrangement of H. capsulatum yeast near to the nucleus of infected murine alveolar macrophages that may contribute to the yeast’s persistence under intracellular conditions, since this fungal pathogen may display different strategies to prevent elimination by the host's phagocytic mechanisms

Genes from Chagas Susceptibility Loci That Are Differentially Expressed in T. cruzi-Resistant Mice Are Candidates Accounting for Impaired Immunity

Variation between inbred mice of susceptibility to experimental Trypanosoma cruzi infection has frequently been described, but the immunogenetic background is poorly understood. The outcross of the susceptible parental mouse strains C57BL/6 (B6) and DBA/2 (D2), B6D2F1 (F1) mice, is highly resistant to this parasite. In the present study we show by quantitative PCR that the increase of tissue parasitism during the early phase of infection is comparable up to day 11 between susceptible B6 and resistant F1 mice. A reduction of splenic parasite burdens occurs thereafter in both strains but is comparatively retarded in susceptible mice. Splenic microarchitecture is progressively disrupted with loss of follicles and B lymphocytes in B6 mice, but not in F1 mice. By genotyping of additional backcross offspring we corroborate our earlier findings that susceptibility maps to three loci on Chromosomes 5, 13 and 17. Analysis of gene expression of spleen cells from infected B6 and F1 mice with microarrays identifies about 0.3% of transcripts that are differentially expressed. Assuming that differential susceptibility is mediated by altered gene expression, we propose that the following differentially expressed transcripts from these loci are strong candidates for the observed phenotypic variation: H2-Eα, H2-D1, Ng23, Msh5 and Tubb5 from Chromosome 17; and Cxcl11, Bmp2k and Spp1 from Chromosome 5. Our results indicate that innate mechanisms are not of primary relevance to resistance of F1 mice to T. cruzi infection, and that differential susceptibility to experimental infection with this protozoan pathogen is not paralleled by extensive variation of the transcriptome

Experimental traumatic brain injury

Traumatic brain injury, a leading cause of death and disability, is a result of an outside force causing mechanical disruption of brain tissue and delayed pathogenic events which collectively exacerbate the injury. These pathogenic injury processes are poorly understood and accordingly no effective neuroprotective treatment is available so far. Experimental models are essential for further clarification of the highly complex pathology of traumatic brain injury towards the development of novel treatments. Among the rodent models of traumatic brain injury the most commonly used are the weight-drop, the fluid percussion, and the cortical contusion injury models. As the entire spectrum of events that might occur in traumatic brain injury cannot be covered by one single rodent model, the design and choice of a specific model represents a major challenge for neuroscientists. This review summarizes and evaluates the strengths and weaknesses of the currently available rodent models for traumatic brain injury